Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.
Pallawi TorkaLevi D PedersonMichael V KnoppDavid PoonJun ZhangBrad S KahlHoward R HigleyGary KelloffJonathan W FriedbergLawrence H SchwartzWyndham H WilsonJohn P LeonardNancy L BartlettHeiko SchöderAmy S RuppertPublished in: Cancer medicine (2023)
These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials.
Keyphrases
- clinical trial
- positron emission tomography
- computed tomography
- diffuse large b cell lymphoma
- pet ct
- phase ii
- epstein barr virus
- pet imaging
- open label
- electronic health record
- double blind
- study protocol
- magnetic resonance imaging
- phase iii
- randomized controlled trial
- contrast enhanced
- magnetic resonance
- deep learning